Invio Software, Inc.
Invio Software, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Invio Software, Inc..
Invio Software, Inc. is a company.
Key people at Invio Software, Inc..
Invio Software, Inc., founded in 2016 and headquartered in Seattle, Washington, develops FDA-compliant, cloud-based software to automate clinical trial workflows, replacing inefficient paper-based methods with digital monitoring and cost management tools.[1][4] The company's flagship product, SourceDrive®, handles clinical trial documents and data quality monitoring for healthcare and clinical research organizations, serving U.S. research sites to improve efficiency, patient safety, and time-to-market for treatments.[1][4] With early traction including partnerships with three research sites and plans to expand to 20 more, Invio has raised around $370K–$800K in seed funding, though its Mosaic Score indicates recent financial challenges.[1][3]
Invio was founded in 2016 by a team of four experienced entrepreneurs—Cassie Wallender, Dema, and two others—who had previously collaborated at successful startups like iLike (acquired by Myspace) and Appature (acquired by IMS Health), gaining expertise in lean product development and healthcare.[3] The idea emerged from co-founder Poppa's frustration running a clinical trial across 40 hospitals, where teams flew in every six weeks to review data in 3-ring binders, highlighting the need for remote, automated management.[1] Early milestones include raising over $800K from investors like Seattle Angel Conference, Pipeline Angels, Techstars, and Madrona Venture Labs, plus pitching at GeekWire Summit among 200 applicants, securing validation for their mission to automate clinical trial busywork using data and machine learning.[1][3]
Invio rides the digital transformation wave in clinical trials, addressing inefficiencies in a $50B+ industry plagued by manual processes amid rising demand for faster drug development post-COVID.[1][3] Timing aligns with regulatory shifts toward remote monitoring and FDA encouragement of tech-enabled trials, amplified by market forces like labor shortages in research sites and pressure for cost-effective, safer studies.[1][4] By automating "busy work," Invio influences the ecosystem through enhanced data insights and scalability, potentially lowering barriers for smaller CROs and sites while boosting overall trial success rates in healthtech.[3]
Invio's path forward hinges on scaling beyond seed stage amid a low Mosaic Score, likely by securing growth funding to hit 20+ clients and expand SourceDrive® features like advanced ML analytics.[1] Trends in AI-driven trials, decentralized studies, and regulatory digitization will propel demand, positioning Invio to capture share if it overcomes funding hurdles and leverages its Seattle roots.[1][3] Its influence could grow by empowering more efficient, accessible medical innovation, evolving from niche automator to key player in safer, faster clinical research—ultimately delivering the "more and better medical options" it promises.[4]
Key people at Invio Software, Inc..